--- title: "Flora Growth Corp. Announces Withdrawal of Proposed Public Offering | FLGC Stock News" description: "Flora Growth Corp. (NASDAQ: FLGC) has announced the withdrawal of its proposed public offering of common shares. This decision does not constitute an offer to sell or solicit any securities in jurisdi" type: "news" locale: "en" url: "https://longbridge.com/en/news/273994710.md" published_at: "2026-01-28T05:05:00.000Z" --- # Flora Growth Corp. Announces Withdrawal of Proposed Public Offering | FLGC Stock News > Flora Growth Corp. (NASDAQ: FLGC) has announced the withdrawal of its proposed public offering of common shares. This decision does not constitute an offer to sell or solicit any securities in jurisdictions where it would be unlawful. The company, which will be rebranded as ZeroStack, focuses on decentralized AI asset management and operates a global pharmaceutical distribution business through its subsidiary, Phatebo GmbH. The announcement includes forward-looking statements that involve risks and uncertainties, and the company disclaims any obligation to update these statements. Toronto, Ontario--(Newsfile Corp. - January 28, 2026) - Flora Growth Corp. (NASDAQ: FLGC) (the "Company"), today announced the withdrawal of the proposed public offering of common shares. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. **About Flora Growth Corp.** Flora Growth Corp., which is set to be rebranded as ZeroStack, is the first, Nasdaq-listed, asset management company focused on providing exposure to decentralized AI. The Company also operates a global pharmaceutical distribution business through its wholly owned subsidiary, Phatebo GmbH. For more information, visit https://zerostack.ai/. **Cautionary Statement Concerning Forward-Looking Statements** *This press release may contain "forward-looking statements," as defined by U.S. federal securities laws. Forward-looking statements reflect the Company's current expectations and projections about future events at the time, and thus involve uncertainty and risk. The words "believe," "expect," "anticipate," "will," "could," "would," "should," "may," "plan," "estimate," "intend," "predict," "potential," "continue," and the negatives of these words and other similar words or expressions generally identify forward-looking statements. Such forward-looking statements are subject to various and risks and uncertainties, including those described under section entitled "Risk Factors" in the Company's Annual Report on Form 10-K filed with the United States Securities and Exchange Commission on March 24, 2025 and in the Company's Quarterly Report on Form 10-Q filed with the SEC on November 5, 2025, as such factors may be updated from time to time in the Company's periodic filings with the SEC, which are accessible on the SEC's website at* *www.sec.gov/edgar**. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this release and in the Company's filings with the SEC. While forward-looking statements reflect the Company's good faith beliefs, they are not guarantees of future performance. The Company disclaims any obligation to publicly update or revise any forward-looking statement to reflect changes in underlying assumptions or factors, new information, data or methods, future events or other changes after the date of this press release, except as required by applicable law. You should not place undue reliance on any forward-looking statements, which are based on information currently available to the Company (or to third parties making the forward-looking statements).* To view the source version of this press release, please visit https://www.newsfilecorp.com/release/281907 ### Related Stocks - [ARKG.US - Ark Genomic Revolution ETF](https://longbridge.com/en/quote/ARKG.US.md) - [PJP.US - Invesco Pharmaceuticals ETF](https://longbridge.com/en/quote/PJP.US.md) - [FLGC.US - Flora Growth](https://longbridge.com/en/quote/FLGC.US.md) - [VHT.US - VG Health](https://longbridge.com/en/quote/VHT.US.md) - [IXJ.US - iShares Global Healthcare](https://longbridge.com/en/quote/IXJ.US.md) - [PPH.US - VanEck Pharmaceutical ETF](https://longbridge.com/en/quote/PPH.US.md) - [XPH.US - SPDR Pharmac](https://longbridge.com/en/quote/XPH.US.md) - [IHE.US - iShares US Pharma](https://longbridge.com/en/quote/IHE.US.md) - [XLV.US - Health Care Select Sector SPDR](https://longbridge.com/en/quote/XLV.US.md) - [ZSTK.US - ZeroStack](https://longbridge.com/en/quote/ZSTK.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | Vanda Pharmaceuticals announces FDA approval of Bysanti tablets | Vanda Pharmaceuticals announces FDA approval of Bysanti tablets | [Link](https://longbridge.com/en/news/276504017.md) | | Earnings Outlook For Amneal Pharmaceuticals | Amneal Pharmaceuticals (NASDAQ:AMRX) is set to release its quarterly earnings report on February 27, 2026, with analysts | [Link](https://longbridge.com/en/news/277054476.md) | | Enanta Pharmaceuticals: RSV Monoclonal Headwinds Turn Tailwind for Zelicapavir Treatment Opportunity | Enanta Pharmaceuticals received a Buy rating from analyst Brandon Folkes of H.C. Wainwright, with a price target of $20. | [Link](https://longbridge.com/en/news/276474081.md) | | Recursion Pharma Q4 revenue tops eatimates, helped by Sanofi payments | Recursion Pharmaceuticals reported Q4 revenue of $35.35 million, surpassing analyst expectations of $24.59 million. The | [Link](https://longbridge.com/en/news/276880192.md) | | Corbus Pharmaceuticals Touts “Catalyst-Rich” 2026 With CRB-701 and CRB-913 Data Readouts Ahead | Corbus Pharmaceuticals (NASDAQ:CRBP) announced a "catalyst-rich" 2026 at Oppenheimer’s Healthcare Conference, highlighti | [Link](https://longbridge.com/en/news/277003496.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.